Immunome (IMNM) Competitors $10.30 +0.35 (+3.52%) Closing price 04:00 PM EasternExtended Trading$10.30 +0.00 (+0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNM vs. APLS, MLTX, PTGX, MIRM, MENS, MTSR, BHC, KYMR, SRRK, and AMRXShould you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Mirum Pharmaceuticals (MIRM), Jyong Biotech (MENS), Metsera (MTSR), Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry. Immunome vs. Its Competitors Apellis Pharmaceuticals MoonLake Immunotherapeutics Protagonist Therapeutics Mirum Pharmaceuticals Jyong Biotech Metsera Bausch Health Cos Kymera Therapeutics Scholar Rock Amneal Pharmaceuticals Apellis Pharmaceuticals (NASDAQ:APLS) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability. Is APLS or IMNM more profitable? Apellis Pharmaceuticals has a net margin of -30.24% compared to Immunome's net margin of -1,687.08%. Immunome's return on equity of -76.10% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-30.24% -116.09% -26.72% Immunome -1,687.08%-76.10%-65.14% Does the media refer more to APLS or IMNM? In the previous week, Apellis Pharmaceuticals had 5 more articles in the media than Immunome. MarketBeat recorded 8 mentions for Apellis Pharmaceuticals and 3 mentions for Immunome. Apellis Pharmaceuticals' average media sentiment score of 1.21 beat Immunome's score of 0.94 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, APLS or IMNM? Apellis Pharmaceuticals has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Do analysts prefer APLS or IMNM? Apellis Pharmaceuticals currently has a consensus price target of $34.12, indicating a potential upside of 21.98%. Immunome has a consensus price target of $22.50, indicating a potential upside of 118.45%. Given Immunome's stronger consensus rating and higher possible upside, analysts plainly believe Immunome is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58Immunome 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, APLS or IMNM? Apellis Pharmaceuticals has higher revenue and earnings than Immunome. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$754.65M4.68-$197.88M-$1.82-15.37Immunome$9.04M99.17-$292.96M-$3.08-3.34 Do insiders and institutionals have more ownership in APLS or IMNM? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Comparatively, 7.7% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryApellis Pharmaceuticals beats Immunome on 10 of the 17 factors compared between the two stocks. Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNM vs. The Competition Export to ExcelMetricImmunomeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$896.51M$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-3.3421.1431.1525.96Price / Sales99.17398.37475.15122.97Price / CashN/A43.0937.1558.38Price / Book3.338.079.116.39Net Income-$292.96M-$54.72M$3.26B$265.56M7 Day Performance0.19%2.62%2.11%1.98%1 Month Performance-6.96%7.63%5.12%1.33%1 Year Performance-29.36%13.11%31.25%21.15% Immunome Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNMImmunome1.9847 of 5 stars$10.30+3.5%$22.50+118.4%-34.5%$896.51M$9.04M-3.3440Positive NewsAnalyst ForecastGap UpAPLSApellis Pharmaceuticals4.159 of 5 stars$27.35-1.4%$34.12+24.7%-30.7%$3.50B$781.37M-15.03770News CoverageInsider TradeShort Interest ↑MLTXMoonLake Immunotherapeutics1.6345 of 5 stars$53.73-1.2%$74.43+38.5%+9.8%$3.49BN/A-19.332PTGXProtagonist Therapeutics1.8503 of 5 stars$56.21+0.2%$67.20+19.6%+34.9%$3.49B$434.43M80.30120Positive NewsMIRMMirum Pharmaceuticals3.5229 of 5 stars$66.68-1.8%$74.13+11.2%+67.5%$3.41B$336.89M-55.11140Positive NewsMENSJyong BiotechN/A$41.50-7.2%N/AN/A$3.40BN/A0.0031News CoverageMTSRMetseraN/A$32.39+4.0%$55.00+69.8%N/A$3.27BN/A0.0081BHCBausch Health Cos4.3441 of 5 stars$8.02-3.8%$9.00+12.2%+28.7%$3.09B$9.63B30.8520,700Analyst RevisionKYMRKymera Therapeutics3.0894 of 5 stars$43.62+2.3%$59.11+35.5%-12.3%$3.05B$47.07M-12.57170SRRKScholar Rock4.5802 of 5 stars$31.52+0.4%$45.14+43.2%+273.5%$3.02B$33.19M-10.83140News CoveragePositive NewsAnalyst ForecastAMRXAmneal Pharmaceuticals3.3522 of 5 stars$9.26-2.0%$11.60+25.3%+17.1%$2.97B$2.85B926.938,100News CoveragePositive News Related Companies and Tools Related Companies APLS Competitors MLTX Competitors PTGX Competitors MIRM Competitors MENS Competitors MTSR Competitors BHC Competitors KYMR Competitors SRRK Competitors AMRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access